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Objective: Paraplegia remains a serious complication of thoracic and thoracoabdominal aortic operations. To avoid this
dreadful complication, N-methyl-D-aspartate (NMDA) receptor antagonists have been examined in the ischemic or
excitotoxic neuronal injury model. In the present study, we evaluated the protective efficacy of NMDA receptor
antagonists that were infused segmentally after aortic clamping, as a spinoplegia, to reduce aspartate neurotoxicity in the
spinal cord.
Methods: Infrarenal aortic isolation was performed in New Zealand white rabbits. Group A animals (n  7) were
pretreated with the segmental infusion of MK-801, a noncompetitive NMDA receptor antagonist, followed by segmental
aspartate (50 mmol) infusion for 10 minutes. Group B animals (n  6) received pretreatment with CGS19755, a
competitive NMDA receptor antagonist, followed by the same aspartate infusion as group A. Group C animals (n  7)
received vehicle only, followed by aspartate infusion as a control group. In addition, group D animals (n  6) were
pretreated with MK-801 that was administrated intravenously 1 hour before aspartate infusion. Neurologic status was
assessed at 12, 24, and 48 hours after operation by using the Tarlov score. The spinal cords were procured at 48 hours
for histopathologic analysis to determine the extent of excitotoxic neuronal injury.
Results:Most of the animals in groups A and D revealed full recovery or mild motor disturbance. Group B and C animals
exhibited paraplegia or paraparesis with marked neuronal necrosis. In the Tarlov score at 48 hours, group A animals
represented better neurologic function than group C (P < .01) and similar motor function to group D animals. Severe
histopathologic change was not observed in groups A and D. Animals in groups A and D showed a greater number of
motor neurons than animals in groups B and C (P < .01). The difference could be due to chance between group A and
D animals (P  .08).
Conclusions: These results showed that the segmental infusion of noncompetitive NMDA receptor antagonist as an
intraoperative spinoplegia could have a protective effect on the spinal cord neurons against excitotoxic neuronal injury in
vivo. On the other hand, efficacy of the use of competitive antagonist was suggested to be limited in this model, probably
because of the insurmountable obstacle of the blood-brain barrier. ( J Vasc Surg 2005;42:765-71.)
Clinical Relevance: Paraplegia is a devastating complication during surgical repair of the thoracic and thoracoabdominal
aortas. Excitatory amino acids neurotoxicity through the N-methyl-D-aspartate (NMDA) receptor is no doubt the
pathologic hallmark of ischemic and postischemic spinal cord injury. Systemic administration of either a competitive or
noncompetitive NMDA antagonist has been reported to have neuroprotective effect, in terms of preoperative treatment,
with dose-related central sympathomimetic and sedative effects. Local administration, particularly of a noncompetitive
NMDA antagonist, infused segmentally after aortic clamping could therefore be a potent intraoperative pharmacologic
strategy to minimize the effective dose that retains NMDA antagonism without undesirable adverse effects. Our ability
to reproduce this model could facilitate pharmacologic prevention or provide a new surgical technique as a spinoplegia for
NMDA receptor-mediated neuronal injury.Paraplegia is a devastating complication of surgical
repair of the thoracic and thoracoabdominal aortas. The
incidence varies between 1% and 30%, depending on the
extent of the aneurysm, dissection, rupture, and aortic
clamping time.1-4 Surgical techniques, such as distal perfu-
sion, hypothermia, spinal fluid drainage, and segmental
repair of intercostal arteries, or protective pharmacologic
strategies have been developed to reduce the occurrence of
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doi:10.1016/j.jvs.2005.05.052this complication by either maintaining adequate spinal
cord perfusion or increasing spinal cord ischemia toler-
ance.3-5 However, no method yet completely avoids this
dreadful complication.
Excitatory amino acids (EAAs), mainly glutamate and
aspartate, are major excitatory neurotransmitters in the
central nervous system, including the spinal cord. EAAs are
also well known to have neurotoxicity under metabolic
stress in a manner of activating N-methyl-D-aspartate
(NMDA) receptor and -amino-3-hydroxy-5-methyli-
soazole-4-propionic acid (AMPA) receptor.6-9 Many clini-
cal and experimental reports have revealed that EAAs con-
tribute to the irreversible and fatal neuronal injury during
and after ischemia in the spinal cord; nevertheless, it has
been difficult to indicate EAA neurotoxicity in vivo.10
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mental effects of exogenous aspartate on the spinal cord neurons
under metabolic stress in vivo.9 Aspartate is a potent NMDA
receptor agonist that is well attenuated by local injection or
intravenous administration of NMDA receptor antagonists such
as the noncompetitive antagonist ()-5-methyl-10,11-dihydro-
5H-dibenzo[a,d]cycloheptan-5,10-imine (MK-801) and the
competitive antagonist cis-4-phosphonomethyl-2-piperidine-
carboxylic acid (CGS19755).6,11-17
In a study using a rabbit model, the intravenous admin-
istration of MK-801 (5 mg/kg) starting immediately after
spinal cord injury was reported to improve motor recovery
and reduce edema formation.14 Acute therapy with the
intravenous administration of CGS19755 (30 to 40 mg/
kg) was also evaluated using a rabbit model of spinal cord or
focal cerebral ischemia and revealed significant protective
effect against ischemic neuronal injury.15,16 In a recent
study, we showed that the preoperative intravenous admin-
istration of either MK-801 (6 mg/kg) or CGS19755 (30
mg/kg) had a protective effect on the spinal cord neurons
against EAA neurotoxicity.17
Evidences were confirmed that treatment of NMDA
receptor antagonists ameliorates neuronal injury; however,
the effects of segmental infusion have not yet been deter-
mined. The purpose of this study was, therefore, to evaluate
the protective effect of the segmental infusion of a NMDA
receptor antagonist against aspartate neurotoxicity in the
spinal cord. In the present study, we administrated two
types of NMDA receptor antagonists, MK-801 and
CGS19755, immediately after aortic clamping that was
designed as a segmental infusion of spinoplegia.
MATERIAL AND METHODS
Subjects. Male New Zealand white rabbits weighing
3.0 to 3.5 kg were used for this study. All experimental
animals received humane care and treatment in compliance
with theGuide for the Care and Use of Laboratory Animals,
Institute of Laboratory Animal Resources, Commission of
Life Science, National Research Council (Washington: Na-
tional Academy Press, 1996). This study was approved by
the Keio University Institutional Review Board.
Experimental Model. Animals were anesthetized
with 1.5% halothane and 98.5% oxygen and were placed in
the supine position, maintaining spontaneous breathing.
Rectal temperature was kept normal (39°C) with a heating
mattress. A median laparotomy was used, and the abdom-
inal aorta was dissected just inferior to the left renal vein and
above the bifurcation.Heparin sulfate was used for systemic
anticoagulation. A 20-gauge catheter was introduced from
the femoral artery to the abdominal aorta, and the tip of the
catheter was placed 5 mm above the bifurcation.
The abdominal aorta was clamped inferior to the left
renal vein, and the femoral catheter was snared around
the bifurcation. The posterior mesenteric artery was also
clamped with a vascular clip. Thus the abdominal aorta was
isolated with six or seven lumbar arteries. All the rabbits
pretreated with segmental infusion received protectiveagent or vehicle (saline) via the femoral arterial catheter
immediately after aortic isolation.
Neuronal injury in the spinal cord was induced by the
methods previously described.9 Briefly, after pretreatment,
aspartate solution, which had been incubated at normal
body temperature (39°C) and adjusted to the physiologic
osmolarity, was infused into the isolated aortic segment via
the femoral catheter at a rate of 2 mL/min for 10 minutes.
At the end of the infusion, all the clamps were released and
the snare around the bifurcation loosened. The abdomen
was closed after the femoral arterial catheter was removed.
Pretreatment with NMDA receptor antagonist.
MK-801 was obtained from Merck Research Laboratories
(Rathway, NJ). CGS19755 was from Novartis Pharmaceu-
ticals Research (Summit, NJ). These compounds were dis-
solved in saline and incubated at 39°C.
Group A rabbits (n 7) were pretreated with the local
administration of MK-801 (4 mg/kg), which was infused
promptly after aortic isolation in a fashion not to exceed the
mean arterial pressure via the femoral catheter, and received
a segmental infusion of aspartate (50 mmol) at a rate of
2 mL/min for 10 minutes.
Group B rabbits (n  6) received pretreatment with
CGS19755 (30 mg/kg) followed by the same aspartate
infusion as group A.
Group C rabbits (n  7) received only vehicle (saline)
followed by aspartate infusion as a control group.
Group D rabbits (n 6) were pretreated withMK-801
(4mg/kg) that was administrated intravenously for 3 hours
beginning 1 hour before the same segmental infusion of
aspartate (50 mmol) via the femoral catheter (MK-801
intravenous).
Five animals were also treated identical to groups A and
B but did not undergo aortic clamping (MK-801 and
CGS19755 sham).
Neurologic and histopathologic evaluation. Hindlimb
function was evaluated at 12, 24, and 48 hours after oper-
ation according to the modified Tarlov score (5  normal
hop, 4 weak hop, 3 sits alone, 2 sits with assistance,
1  slight movement, 0  no movement). At 48 hours,
animals were reanesthetized and sacrificed with an overdose
of intravenous pentobarbiturate. The spinal cord was fixed
by a perfusion of 10% formaldehyde solution via the femo-
ral arterial catheter in the same manner as the first opera-
tion, followed by immersion fixation for 2 weeks.
Cross-sections from the lower thoracic to the sacral
cord were stained with hematoxylin and eosin and Luxol-
fast blue. For quantitative histopathologic analysis, motor
neurons were counted by the methods previously de-
scribed.18 Briefly, spinal cords were cut into 10-mm slices
from the bifurcation of the third sacral nerve. Motor neu-
rons of normal appearance were counted in each segment
of 10 mm, 30 mm, and 50 mm proximal from the third
sacral nerve. A normal-appearing motor neuron was de-
fined as 30 m in size, having no eosinophilic change,
and having a clear nucleolus without karyolysis. His-
topathologic assessment using a light microscopy was done
by a neuropathologist blinded to experimental groups.
sedat
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SD. Statistical significance of hindlimb function was ana-
lyzed among the four experimental groups by the Kruskal-
Wallis test followed by the Dunn’s test for all pair-wise
comparisons. We compared numbers of normal-appearing
motor neurons using two-way Bonferroni analysis of vari-
ance (ANOVA) and physiologic parameters using one-way
ANOVA. Data were considered statistically significant at a
value of P  .05.
RESULTS
In groups A and D, most of the rabbits could not be
evaluated because of the sedative effect of MK-801, which
lasted for12 hour after operation. In group A, two of the
seven rabbits recovered fully, showing normal hop (Tarlov
5), and the other three exhibited mild disturbance of motor
function (Tarlov 4) at 48 hours (Table I). In group D, one
of the six recovered fully, and three exhibited mild distur-
bance of motor function at 48 hours. In group B, pre-
treated with CGS19755, five of the six rabbits exhibited
paraplegia (Tarlov 0) or paraparesis (Tarlov 1) at all the
time points (Table I). All group C animals exhibited para-
plegia or paraparesis at 48 hours. The median Tarlov score
at 48 hours was 4.0 in group A, 5.0 in group B, 0.0 in group
C, and 4.0 in group D. Group A animals, pretreated with
segmental infusion of MK-801, had significantly better
neurologic score compared with group C (P  .01) and
showed a similar score to group D animals (P  .28). The
differences could be due to chance between group B and
group C animals (P  .40).
Most of the rabbits in groups A and D demonstrated
normal histology (Fig 1). Some rabbits that exhibited dis-
turbance of motor functions showed minimal neuronal
degeneration with shrinkage or eosinophilic change. How-
ever, these focal lesions were found in one of several sec-
tions of the sacral cord. Histopathology revealed severe
neuronal injury in groups B and C. Sections from these
groups exhibited severe and extensive gray matter necrosis
with prominent vacuolation and numerous degenerated
neurons that were predominantly localized in the anterior
horns of the lower thoracic and sacral cord. Degenerated
neurons were irregularly shrunken or exhibited eosino-
philic structureless cytoplasm with their nuclei stained hy-
Table I. Neurologic outcomes
12 hours
Talrov
score
Group
A*
Group
B
Group
C
Group
D*
Group
A
G
5 1 0 0 0 2
4 2 0 0 1 3
3 0 0 0 1 2
2 0 1 1 0 0
1 0 3 1 0 0
0 0 2 5 0 0
Group A: MK-801 segmental (n  7); Group B: CGS19755 (n  6); Grou
*The motor function of some rabbits could not be evaluated because of theperchromatic (Fig 2).The average number of normal-appearing motor neu-
rons among experimental groups in each spinal cord seg-
ment is indicated in Fig 3. Group A and D animals had
significantly more normal-appearing motor neurons than
hours 48 hours
Group
C
Group
D
Group
A
Group
B
Group
C
Group
D
0 1 2 0 0 1
0 3 3 0 0 3
0 1 2 0 0 1
1 1 0 1 0 1
1 0 0 3 2 0
5 0 0 2 5 0
control (n  7); Group D: MK-801 intravenous (n  6).
ive effect of MK-801.
Fig 1. Representative photomicrographs of histologic sections of
the spinal cord (stained with hematoxylin and eosin and Luxol-fast
blue) from group A showing normal histology. Animals received
pretreatment with MK-801 followed by segmental aspartate infu-
sion. Spinal cord neurons were well protected by the segmental
infusion of MK-801 (arrows).24
roup
B
0
0
0
1
3
2
p C:group B and C animals in all the segments of the spinal cord
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group B and C animals (P  .73). Animals in group A,
pretreated with segmental infusion of MK-801, showed
greater number of normal-appearing motor neurons than
those in group D, pretreated with intravenous administra-
tion (Fig. 3); however, there was no significant difference
between the two groups (P  .08)
Sham animals in each group exhibited full recovery at
48 hours after operation, although most of the animals
receiving MK-801 showed the same sedative effect as those
in groups A and D. Sections from those demonstrated
normal histology.
Rectal temperatures, before aortic clamping, were sim-
ilar in groups A, B, C and D. The differences could be due
to chance among four groups in mean systemic blood
Fig 2. Representative photomicrographs of histologic sections of
the spinal cord (stained with hematoxylin and eosin and Luxol-fast
blue) from group B and group C demonstrating aspartate neuro-
toxicity. A, Section from group B (pretreated with CGS19755)
exhibited severe and extensive gray matter necrosis (arrow heads).
B, Section from group C received segmental aspartate infusion
without pretreatment. Degenerated neurons were irregularly
shrunken and exhibited structureless cytoplasm with their nuclei
stained hyperchromatic (arrows).pressure and heart rate during the experiment (Table II).DISCUSSION
Spinoplegia was first described in the article by Svens-
son et al,19 in which segmental infusion of single dose of
cold crystalloid with lidocaine was found to be effective in
reducing the severity of ischemia during aortic clamping.
Particularly, segmental infusion of spinoplegia was reported
to be useful for detecting critical arteries that supply the
spinal cord.19,20 Moreover, the local administration of a
pharmacologic agent might reduce undesirable adverse ef-
fects that could occur when administrated intravenously.
The main finding in the present study was that the
segmental infusion of the noncompetitive NMDA receptor
antagonist MK-801, which was infused immediately after
aortic clamping as a type of spinoplegia, had a protective
effect on the spinal cord neurons against EAA-induced
neuronal injury; whereas the competitive NMDA receptor
antagonist CGS19755 did not reveal neuroprotective effect
by segmental infusion. This finding was also of interest
because we had previously documented in a rabbit model
using NMDA receptor antagonists that the intravenous
administration of CGS19755 (30 mg/kg) 1 hour before
the insult could have protective effect on the spinal cord
neurons against aspartate-induced neurotoxicity.17
Competitive NMDA receptor antagonists directly block
the glutamate recognition site dose-dependently. These com-
pounds are generally quite polar and show very slow brain
uptake in animal studies.16,21 In the present situation, high
concentrations of exogenous agonist (aspartate) at the
NMDA receptor would overcome the block produced by a
competitive antagonist. On the other hand, noncompeti-
tive NMDA receptor antagonists, which act at the NMDA
receptor-operated ion channel as a open channel blocker,
are extremely lipophilic and can reach high levels in the
brain rapidly after administration.11,21 Furthermore, in the
presence of a noncompetitive antagonist that showsmarked
agonist dependence, a low physiologic level of NMDA
receptor activation could occur, but if this is increased to
pathologic levels, excessive activation of the receptor would
bring about the noncompetitive block.12 We estimate that
it would be difficult to show the protective effect of com-
petitive NMDA antagonists in acute therapy or preopera-
tive administration just before the neuronal injury.
Aspartate, present ubiquitously in the central nervous
system, is a major excitatory neurotransmitter and a potent
NMDA receptor agonist. The overactivation of NMDA
receptor causes calcium ion influx, and it is followed by
activation of several calcium-dependent enzymes that lead
to irreversible and fatal neuronal degeneration.6,9 Since
Choi et al22 demonstrated aspartate neurotoxicity in vitro,
it has been difficult to show aspartate neurotoxicity in vivo.
The defense mechanism against EAA neurotoxicity is as-
sumed to be due to the activity of rapid and high-affinity
reuptake systems that maintain the extracellular aspartate
concentration within a nontoxic level.9,23
In the present study, the given dose of aspartate in the
sham group was cleared by the reuptake systems without
toxic effect. Thus, we performed infrarenal aortic clamping
.01) (
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more, segmental infusion of aspartate solution (50 mmol)
increased the concentration to a level exceeding the physi-
ologic range of aspartate release.
The histopathologic findings in groups B (pretreated
Fig 3. The average number of normal-appearing motor
from the third sacral nerve. Group A and D animals show
group B and C animals in all the segments (P  .01). Th
animals (P  .73). Animals in group A (pretreated wit
of normal-appearing motor neurons than animals in gro
there was no significant difference between two groups (
difference between group A and group B; and group
group D and group B; and group D and group C (P 
Table II. Physiologic parameters
Group A
Body temperature (°C) 39.4  0.4
Mean arterial blood
pressure (mm Hg) 51.7  1.6
Heart rate (beats/min) 322  35
Data are mean  SDwith CGS19755) and C (no pretreatment) showed severelyinjured gray matter, with prominent vacuolation and numer-
ous degenerated neurons that were irregularly shrunken or
lightly eosinophilic with their nuclei stained hyperchromatic.
In contrast, the white matter was relatively spared, even in the
severely injured sections. These pathologic findings were typ-
ons in the level of 10 mm, 30 mm and 50 mm proximal
gnificantly more normal-appearing motor neurons than
ference could be due to chance between group B and C
gmental infusion of MK-801) showed greater number
(pretreated with intravenous administration); however,
08). All values are presented as mean  SE. *Significant
group C (P  .01). **Significant difference between
two-way analysis of variance).
roup B Group C Group D
.1  0.6 39.6  0.6 39.1  0.6
.6  1.6 51.0  4.0 49.8  2.1
4  22 335  12 327  17neur
ed si
e dif
h a se
up D
P  .
A andG
39
52
31ical in the setting of EAA neurotoxicity.7,9,24
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minimal neuronal degeneration; however, these sections
were proved to have a significantly greater number of
motor neurons compared with other groups. Particularly,
the average number of normal-appearing motor neurons in
group A animals (MK-801 segmental) was similar to those
of sham animals that revealed normal histology (data not
shown). It was also demonstrated to be greater than in
group D animals (MK-801 intravenous), although there
was no significant difference between the two groups (P 
.08). These results suggested that segmental infusion,
rather than systemic administration, of noncompetitive
NMDA antagonist would be a potent pharmacologic strat-
egy that could retain neuroprotective effect and ameliorate
undesirable adverse effects.
During preliminary experiments in this model using
various doses of MK-801 (2 mg/kg, 3 mg/kg, 4 mg/kg,
and 6 mg/kg) and CGS19755 (10 mg/kg, 20 mg/kg, 30
mg/kg, and 40 mg/kg), we observed that the dose result-
ing in paraplegia in 50% of animals should lie between 3
mg/kg and 4 mg/kg for MK-801 and between 10 mg/kg
and 20mg/kg for CGS19755.We used segmental infusion
of MK-801 (4 mg/kg) and CGS19755 (30 mg/kg) in a
relatively high dose, because the initial dose should be high
enough to penetrate the blood-brain barrier and to block
the vicious cascade that leads to irreversible and fatal neu-
ronal injury.
Most researchers have abandoned NMDA receptor
antagonists because human and animal studies have shown
that both MK-801 and CGS 19755 have some adverse
effects, such as central sympathomimetic and sedative ef-
fects. Central sympathomimetic effects observed in animal
tests are presumed to be the basis for the few dose-related
side effects described in humans. These side effects are
restlessness, jitteriness, and agitated confusion.11,16 In the
present study, only animals pretreated with MK-801 re-
vealed sedative effects that were eliminated within 24
hours, and some of these animals showed temporary central
sympathomimetic effects such as restlessness and agitated
confusion. However, we believe that these adverse effects
might be acceptable in trade for protection against irrevers-
ible and fatal neuronal injury.
The study regarding spinoplegia showed that segmen-
tal infusion of a protective agent was effective in reducing
the severity of ischemia during aortic clamping as measured
by spinal motor evoked potentials.19,20 Thus, in the con-
cept of spinoplegia as a means of protecting the spinal cord,
it might be necessary to show the data, such as spinal motor
evoked potentials and spinal somatosensory evoked poten-
tials, to prove that we actually arrested the spinal cord.
However, potential neuroprotective agents that act at the
NMDA receptor channel complex are widely accepted to
reduce neuronal metabolism in a manner of limiting exci-
tatory neurotransmission.12,25,26
CONCLUSION
The segmental infusion of a noncompetitive NMDA
receptor antagonist as an intraoperative spinoplegia couldhave protective effect on the spinal cord neurons against
EAA-induced neuronal injury in vivo. On the other hand,
the efficacy of the use of competitive antagonist was sug-
gested to be limited in this model, probably because of the
blood-brain barrier. Our model may be useful in exploring
themechanism of NMDA receptor-mediated neurotoxicity
and to evaluate the ability of protective agents to reduce
excitotoxic neuronal injury in the spinal cord.
We gratefully acknowledge the help of Takashi Kimura
with the pathologic analysis.
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